These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31567595)

  • 1. Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey.
    Bath R; Bucholz T; Buros AF; Singh D; Smith KE; Veltri CA; Grundmann O
    J Addict Med; 2020; 14(3):244-252. PubMed ID: 31567595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Kratom use and health impact in the US-Results from an online survey.
    Grundmann O
    Drug Alcohol Depend; 2017 Jul; 176():63-70. PubMed ID: 28521200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the self-reported motivations of kratom (
    Grundmann O; Veltri CA; Morcos D; Knightes D; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):433-444. PubMed ID: 35389321
    [No Abstract]   [Full Text] [Related]  

  • 4. Distinct kratom user populations across the United States: A regional analysis based on an online survey.
    Nicewonder JA; Buros AF; Veltri CA; Grundmann O
    Hum Psychopharmacol; 2019 Sep; 34(5):e2709. PubMed ID: 31347212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study.
    Schimmel J; Amioka E; Rockhill K; Haynes CM; Black JC; Dart RC; Iwanicki JL
    Addiction; 2021 Jan; 116(1):176-181. PubMed ID: 32285981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic.
    Garcia-Romeu A; Cox DJ; Smith KE; Dunn KE; Griffiths RR
    Drug Alcohol Depend; 2020 Mar; 208():107849. PubMed ID: 32029298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and characteristics of self-reported kratom use in a representative US general population sample.
    Covvey JR; Vogel SM; Peckham AM; Evoy KE
    J Addict Dis; 2020; 38(4):506-513. PubMed ID: 32657217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kratom as a substitute for opioids: Results from an online survey.
    Coe MA; Pillitteri JL; Sembower MA; Gerlach KK; Henningfield JE
    Drug Alcohol Depend; 2019 Sep; 202():24-32. PubMed ID: 31284119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.
    Singh D; Müller CP; Vicknasingam BK
    Drug Alcohol Depend; 2014 Jun; 139():132-7. PubMed ID: 24698080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey.
    Grundmann O; Veltri CA; Morcos S; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT
    Exp Clin Psychopharmacol; 2023 Oct; 31(5):963-977. PubMed ID: 36634016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.
    Smith KE; Lawson T
    Drug Alcohol Depend; 2017 Nov; 180():340-348. PubMed ID: 28950240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-Report Data on Regular Consumption of Illicit Drugs and HIV Risk Behaviors after Kratom (
    Saref A; Suraya S; Singh D; Grundmann O; Narayanan S; Swogger MT; Prozialeck WC; Boyer E; Balasingam V
    J Psychoactive Drugs; 2020; 52(2):138-144. PubMed ID: 31682782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults.
    Smith KE; Dunn KE; Rogers JM; Garcia-Romeu A; Strickland JC; Epstein DH
    J Addict Med; 2022 Nov-Dec 01; 16(6):666-670. PubMed ID: 35220331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia.
    Singh D; Müller CP; Vicknasingam BK; Mansor SM
    J Psychoactive Drugs; 2015; 47(2):125-31. PubMed ID: 25950592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects.
    Saref A; Suraya S; Singh D; Grundmann O; Narayanan S; Swogger MT; Prozialeck WC; Boyer E; Chear NJY; Balasingam V
    J Ethnopharmacol; 2019 Jun; 238():111876. PubMed ID: 31014959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kratom exposures reported to United States poison control centers: 2011-2017.
    Post S; Spiller HA; Chounthirath T; Smith GA
    Clin Toxicol (Phila); 2019 Oct; 57(10):847-854. PubMed ID: 30786220
    [No Abstract]   [Full Text] [Related]  

  • 18. Home induction and outpatient treatment of kratom use disorder with buprenorphine-naloxone: A case report in a young adult.
    Schmuhl KK; Gardner SM; Cottrill CB; Bonny AE
    Subst Abus; 2020; 41(3):311-314. PubMed ID: 31644379
    [No Abstract]   [Full Text] [Related]  

  • 19. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
    Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
    J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public Perceptions toward Kratom (
    Singh D; Narayanan S; Suraya S; Saref A; Grundmann O; Prozialeck WC; Corazza O; Swogger MT; Griffin O; Balasingam V
    J Psychoactive Drugs; 2020; 52(3):282-288. PubMed ID: 32153252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.